Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


BOC Group/Ohmeda suits v. Inhalon employees seek to bar marketing of generic isoflurane, enflurane.

Executive Summary

BOC GROUP/OHMEDA SUING INHALON AND EMPLOYEES OVER 39424ISOFLURANE AND ENFLURANE, charging breach of contract by four former Ohmeda employees, conspiracy and misappropriation and misuse of trade secrets to manufacture the inhalation anesthetics. BOC Group, its Ohmeda Pharmaceutical Products Division anesthetics operations (formerly Anaquest) and its Puerto Rico manufacturing arm Ohmeda Caribe announced March 29 that suits have been filed against Bethlehem, Penn.-based Inhalon Pharmaceuticals in the Court of Common Pleas in Northampton County, Penn. that seek monetary damages and an injunction to prevent Inhalon from marketing isoflurane and enflurane.

You may also be interested in...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts